Plandai Biotechnology, Inc. is a fully reporting SEC company, publicly traded on the OTC Market under the symbol, "PLPL". As such, Business, operational and financial information on PLPL is fully transparent and available to public view. A/S : 500 million confirmed / State of Nevada
O/S : End of 2013 ................................110.000.000
Free Float: unknown (word is 15.000.000 only)
Incorporated in: NV,USA
Year of Inc.: 2012
Signature Stock Transfer, Inc.
Transfer Agent, 2632 Coachlight Ct., Plano, TX, 75093
Plandai Biotechnology, Inc. Featured in Farmer's Weekly, South Africa's Oldest Agricultural Magazine
Article Discusses Challenges and Opportunities on Plandai Senteeko Tea Estate
SEATTLE, WA--(Marketwired - Oct 16, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has been featured in the October 18th edition of Farmer's Weekly (www.farmersweekly.co.za). The article discusses the history of South African tea farming, the changes and renovations implemented by Plandaí to rejuvenate the tea industry, and the potential impact of the business on the local economy.
The tea industry in South Africa collapsed in the 1990's when the government subsidies were abolished. The large plantations were abandoned and, in the case of the Senteeko Estate, eventually purchased by the government and then given to the Shamile Community as part of a land claim settlement. With tea farming being labor intensive, the higher labor cost in South Africa resulted in a commodity that was not competitive in the world market. Plandaí's model, which transforms a commodity into a valuable nutraceutical and pharmaceutical extract, is less price sensitive as the labor component is minimized. Plandaí has recently completed construction of a 8,000m2 factory in South Africa which will begin producing 60 tons per annum of finished Phytofare™ Catechin extract in January 2014 from the initial 300 hectares of harvested tea leaf.
Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "We believe that our business model can be adapted to many agricultural regions and products as worldwide competition in commodities drives down prices and the standard of living. Creating value added products is the perfect way to revitalize these extinct industries. The benefit to businesses such as Plandaí is that we can acquire production capacity at a relative bargain, stimulate the local economies, and receive valuable assistance from the government."
Plandaí has posted a copy of the full article on its website, www.plandaibiotech.com, where additional updated photos on the factory are also available.
Plandai Biotechnology, Inc. Announces New Extract in Its Ongoing Fight Against Malaria
Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it is developing a new Phytofare™ botanical extract which combines the phytonutrients from green tea with those from the plant Artemisia annua (commonly called Sweet Wormwood), the synthetic derivative of which is the basis for many current anti-malarial drugs.
Malaria, which still kills nearly a million people every year, has been variously treated over the years with different drugs, including Quinine and, more recently, Artemisinin, a synthetic analog of Artemisia. However, the past few years have seen an increase in drug-resistant strains. The World Health Organization is actively seeking a solution to the Artemisinin-resistant strains of Malaria that have been spreading out of the Cambodia-Thailand border where they were first discovered.
Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "Both Artemisia and Green Tea are known anti-malarials; however, in their natural state, they lack the potency to combat the parasite outside of a laboratory setting. There are several reasons for this. First, the molecules simply are not very biocompatible with human tissue -- absorption is poor. Second, the molecules are metabolized in the gut, which further diminishes their efficacy. Science has tried to overcome these deficiencies by creating synthetic compounds that mimic the natural molecules, but the resultant drug is one that can cause side effects and is more prone to eventual resistance."
Mr. Duffield continued, "Plandaí has, we believe, overcome these obstacles by first creating a highly bioavailable extract that combines both green tea catechins and Artemisia. There are studies that suggest that the combination of these two molecules could have a augmentative effect on overall efficacy. Secondly, by entrapping the resultant nano-particles in Pheroid, we will deliver the phytonutrients directly to the tissue intact. Combined, these technologies will enable us to deliver high dosages of the natural anti-malarial antioxidants directly into the blood stream."
Plandaí, through its wholly-owned subsidiary, Phyto Pharmacare, Inc., has engaged the University of Cape Town, in South Africa, to test this new Phytofare™ compound drug first in animal models. Should the results prove favorable, the company will seek FDA consent to begin a Phase II human clinical trial.
Plandai Biotechnology, Inc. Announces License Agreement to Acquire Nano and Micro Entrapment Technol
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that it has signed an exclusive agreement with North-West University in Potchefstroom, South Africa, that holds the patents and associated intellectual property associated with the entrapment of compounds in long-chain fatty acids-based nano- and micro-particles, known as Pheroid. Under the terms of the world license, Plandai has the exclusive right to use the Pheroid technology with all Phytofare polyene-based extracts, which includes proprietary extracts of most botanical matter, for human and animal use.
The Pheroid technology, developed for a number of applications by Professors Anne Grobler Awie Kotze and Jeanetta du Plessis of North-West University, allows particles to be encapsulated, or entrapped, in different media that can improve absorption through protecting the contents. It is actively used worldwide for industrial and agricultural purposes and has been extensively tested in humans and animals by Professor Grobler where it has shown an ability to significantly increase the level of absorption of the entrapped particles into the bloodstream.
For Plandais purposes, the technology will enable the company to produce Phytofare topical products with significantly enhanced tissue absorption and oral products that can help Phytofare survive intact on its passage through the digestive tract and into the bloodstream. Once in the bloodstream, human cells perceive the Pheroid material as a biological building block and as a source of energy, allowing them to pass through the cell membrane and, by metabolism of the long chain fatty acids, release the valuable phytonutrients directly to the tissues.
Roger Duffield, chairman and chief executive officer of Plandai Biotechnology, commented, This agreement gives us the final piece of the equation to provide a reliable way to deliver Phytofare products in the most efficient and bioavailable form. Botanical extracts, including catechins, carotenoids, and citrus bioflavonoids and limonoids, have always generated amazing laboratory results. But poor bioavailability and gut metabolization of the molecules have prevented these results from being replicated in human trials. We believe that the Pheroid nano-entrapment system will help us deliver our already highly-bioavailable Phytofare products in a pure and unchanged state to the target site.
Under the terms of the agreement, Plandai can develop, test, and then manufacture Phytofare Pheroid (ph2TM) products from different botanical extracts for human and animal use. The first Phytofare product to be entrapped in Pheroid and marketed as an ingredient will be Phytofare Catechin Complex, which is a highly bioavailable extract produced from green tea catechins. The license calls for a 2% annual royalty on net sales of Plandai products that incorporate the Pheroid technology and is exempt for Plandai humanitarian products.
Monday 17 June 2013
Plandai Biotechnology, Inc. Announces Final Shipment of Machinery to South African Production Facility
Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutriceutical, and pharmaceutical, today announced that the final shipment of factory equipment is expected to arrive in Durban, South Africa on the weekend of June 22nd with delivery to the Senteeko tea estate in Mpumalanga Province anticipated by the end of the month. Once the final shipment arrives, installation, calibration and optimization will commence, with an estimated completion by the end of October. This last shipment, including the massive boiler system, forms part of the Company's proprietary extraction process.
Initial harvesting trials have been successfully completed and it was determined that a trained and labor force of 400 employees can hand pick the initial 350 hectares of tea bushes every 30 days. The rejuvenation of the tea estate and replanting of new root stock is expected to increase the hectares of farmed tea bushes to 1,000 hectares by 2018. The Company expects commercial production to commence during November 2013 with a daily volume estimated at 290 kg of total formulated Phytofare™ catechin complex.
During the dormant tea growing period, the processing and extraction facility can be modified with the acquisition of additional equipment to produce a Phytofare™ Limonoid Glycoside Complex formulated as the active ingredient for improvement of respiratory ailments including common cold, sinus, and allergies, the maintenance of capillary integrity, and management of inflammation.
Roger Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "It is an exciting period in the Company's existence as the dreams are now reality. Through the dedication and skills of many amazing people who have contributed to this massive challenge, we can finally achieve better health and wellness through the new Phytofare™ botanicals."
Plandaí Biotechnology, through its wholly owned subsidiaries, farms over 3,600 hectares in Barberton region, Mpumalanga province, South Africa. The Company has rejuvenated 350 hectares of tea bushes, which will increase to 550 hectares acres over the next 3 years, and is supported by the introduction of 1 million tea plantlets a year from its own established nursery to ensure increased tea leaf production to 1000 hectares in 2018.
In published research by United States Department of Agriculture - Food Chemistry 132 (2012) 1156-1160, Phytofare™ carotenoid extract, has shown to have improved bioavailability -- the degree to which a substance becomes available to the target tissue after administration -- far exceeding anything available today. Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label. The Company believes that its technology is the foundation for creating an entirely new family of botanical drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts.
15 May 2013
Plandai Biotechnology, Inc. Announces Positive Anti-Malaria Test Results Using Phytofare™ Extract
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical and pharmaceutical, today announced that the Company's Phytofare™ Catechin Extract has proven effective in killing the malaria parasite, plasmodium falciparum, in analytical tests developed by and conducted under the supervision of Dr. Sanjeev Krishna at the Division of Cellular and Molecular Medicine, Centre for Infection, St George's, London School of Medicine.
In the study, the single and most dominant catechin - Epigallocatechin Gallate (EGCG) - was isolated from Plandai's Phytofare™ extract and its effectiveness compared in killing the P. falciparum parasite against a purified EGCG extract. The results, which are expected to be published soon, showed that the Phytofare™ extract killed the parasite and with a lower dosage than the purified EGCG extract.
Roger Duffield, Chief Executive Officer of Plandai, commented, "These initial findings provide evidence corroborating previous scientific findings that Epigallocatechin Gallate catechin can kill the malaria parasite. This study involving Phytofare™ is the first to show the effectiveness of using a commercial botanical extract, rather than purified extract of EGCG catechin, as an anti-malarial.
"We believe these results validate our decade-long research into the opportunity for using botanical extracts as a means to combat one of the world's great plagues. Dr. Krisha's clinical data indicate that Phytofare™ extract has a stable platform with predictable outcomes, making it a suitable candidate for further investigations. We now have the opportunity evaluate the extract in further studies, including inhibiting the parasite in the glucose transporter and as a potential prophylactic by destroying the sporozoites during their journey from injection into the human blood by the female mosquito to the liver."
Plandai is finalizing agreements to undertake further in vitro and then mouse studies at the University of Cape Town, Department of Clinical Pharmacology, to further validate the antimalarial drug target through greater synergistic activity of the complete Phytofare™ catechin complex containing the total eight catechins, rather than the single isolated Epigallocatechin Gallate (EGCG).
Once all these results have been evaluated, the Company will submit its application with the US Food and Drug Administration to commence Phase II human clinical trials.
Each year, approximately 500 million people worldwide become infected with malaria. Of those infected, roughly 600,000 will die from the disease. The development of vaccine options has so far proved challenging due to the complexity of the parasite. In addition, drug-resistant strains of the parasite are moving across Southeast Asia, prompting the need to develop a new line of drug options.
9 May 2013
Plandai Biotechnology, Inc. Announces Distribution Agreement With Natural Products For Weight Management Product Using Phytof...
Plandai Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced a distribution agreement which grants Natural Products the exclusive rights in South Africa to develop and market a weight management product using Plandai's Phytofare™ Catechin Extract. Natural Products specializes in producing and selling Maxi™ nutraceuticals through an Internet client base and directly to pharmacists and wellness retailers in South Africa.
Plandai's Phytofare™ Catechin Extract is processed to deliver a highly bioavailable, antioxidant-rich material to a level many times that of other green tea extracts available on the market. Research has shown that green tea gallate catechins are extremely active antioxidants and in a bioavailable form, are able to protect the red and white blood cells against attack. While not a cure, Phytofare™ Catechin Extract offers meaningful disease prevention, particularly for patients suffering from a compromised immune system, through infections, viruses, malaria and other parasitic infections.
Green tea has long been recognized for its weight management benefits including fat reduction, increased metabolism and improved endurance during exercise. These benefits will be the focus of the weight loss product using Phytofare™ Catechin Extract.
"Natural Products is a dynamic and innovative South African company, and we believe it will excel in developing and marketing a weight loss product using Phytofare™ Catechin Extract," said Callum Baylis-Duffield, Vice-President and Global Director, Marketing Sales for Plandai Biotechnology.
"We are excited to have the opportunity to work with Plandai on the development of this weight management product and believe it has tremendous potential in the South Africa market," said Warren Booth of Natural Products."
In published USDA studies, Plandai's proprietary plant extracts, including Phytofare™ Catechin Extract, Phytofare™ Glucoside Complex and Phytofare™ Carotenoid Extract, have shown to have improved bioavailability – the degree to which a substance becomes available to the target tissue after administration – of between 60-80%, far exceeding anything available today. Superior levels of bioavailability simply mean that the body can actually receive the benefits promised on the product label.
The Company believes that its technology is the foundation for creating an entirely new family of drugs that can treat a multitude of diseases and conditions safely and affordably using naturally-derived extracts.
For additional press releases please visit: www.plandaibiotech.com/press-release.html
_______________________________________________________________________________________________________________________________________________________________________________________________________________________________________ Management Team
President, Chief Executive officer and member of the Board of Directors
Vice-President and Global Director: Marketing
Chief Financial Officer and member of the Board of Directors
Investor Relations and member of the Board of Directors
Address: 2226 Eastlake Ave E, #156
Seattle, Washington, 98102, USA
Phone: (425) 466-0212
Website: http://www.plandaibiotech.com Email: Info@plandaibiotech.com
LIST OF RESEARCHES, COVERAGE, ETC. : http://www.cpreports.com/2013/05/22/ray-dirks-research-plandai-biotechnology-plpl-may-23-2013-by-ray-dirks/
............................... " Ray Dirks Research is projecting price targets for Plandaí Biotechnology, Inc. of $1.00 for the Short Term (6 to 9 Months) and $3.00 for the Long Term (1 to 3 Years)." http://www.goldmanresearch.com/Search.html?ordering=&searchphrase=all&searchword=plandai ................................ "As commercialization and further testing occurs, the shares should approach the $2.00 level in 2013." http://www.otcjournal.com ..................".....I've always had a 2013 price target on PLPL of $1.00. Based on the last 10 days, it looks like I'll be right on this one. I hope you own PLPL."
OTC-Journal - August 13th, 2013
Plandai (PLPL): The Magic Weight Loss Elixir
"Health Enhancement will be the largest health care industry in the 21st Century."
Dr James Canton, Ph.D. and world renown Global Futurist (globalfuturist.com)
What's the size of the market for weight loss products? According to MarketData, a leading independent research firm and it's 420 page study, it's $61 Billion- yes- that's Billion with a "B".
Adding to the frustration of the consumer is the lack of effective prescription medications that work. There are no blockbuster diet pills- none have shown they can be effective helping consumers lose more than 5% of body weight.
The key component for driving substantial sales in this arena and establishing credibility? -It's the Clinical Trial. The big consumers in this area want to see the proof. The Whole Foods of the world want the data. The beverage manufacturers that might include Phytophare in their offering want evidence. Distributors want to make claims they are selling something better.
Plandai's Green Tea Extract- trade marked Phytofare by the company, is getting ready to dive into its first formal clinical trial. The company is convinced they have a virtual miracle health product, and are planning to prove it.
In about a month 90 humans will start ingesting Phytofare. Some will get a placebo. The study is being managed by an independent firm. Full blood panels, weight, and changes in body fat and mood will be measured.
In the end, Plandai (PLPL) expects to prove Phytofare effectively enhances weight loss, reduces hypertension, reduces cholesterol.
Many have tried this and failed. Why Plandai (PLPL)? I can be summed up in one word- Bioavailability.
Most products are 2% to 13% Bioavailble. Another words, when you ingest the stuff, only 2% to 13% ends up finding its way into your blood stream.
Because Phytophare is so concentrated thanks to PLPL's proprietary and patented extraction process, a cup of their stuff is equivalent to a gallon of everyone else's, and it's proven to be substantially more bioavailable than any other product.
Clinical results drive stock prices in the biotech world. Witness what happened with OTC Journal featured stock Inovio (INO) - $.67 to $3 in 3 months. Back at $1.50, we'll be looking at it again.
Technically, PLPL looks as if it could start heading north again any day now.
As you can see, the first four months of 2013 were extremely good for PLPL shareholders. This little stock moved up 5 fold from under $.10 to $.50. Share buyers clearly believe they have something. special.
From early May PLPL has been trading sideways on lighter volumes. This is called a "basing period". a 3 1/2 month base is pretty long. The longer the base, the bigger the move when it starts.
This 3 1/2 months has given anyone who wanted out ample opportunity to do so.
PLPL is getting ready to start growing and harvesting its green tea in South Africa. It can grow and harvest a fuill crop every month.
They have signed a number of global distribution agreements for Phytophare, so as soon as its extracted and available, sales will commence.
Note the company's timing- the studies will be published in conjunction with the product roll out.
If this becomes the de Facto choice in the neutracueticals sector, there's no limit to how high PLPL can head. It's likely headed to about $1 to start its next base.
Now you know why this stock solidly camped above its 200 DMA (red), and right on its 50 DMA (blue). It's in a long term and short term up trend, and the next volume surge should start a renewed climb.
$1 for its next base, but the right trial results, and we could be looking at hundreds of millions in sales. There's your real, long term upside.
Farm of PLANDAI BIOTECHNOLOGY at Africa